Skip to content

Assertio Therapeutics, Inc

Delisted

CIK 1005201fmd_1BHJ8V9FDB7MQKMNT81WTYF55NManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Mar 31, 2020, 41 periods

Latest annual · FY2019

Millions
Total revenues
230
Gross profit
308
Operating income
(194)
Net income
(217)
Free cash flow
89

Latest quarter · Q1 FY2020

Millions
Total revenues
21
Operating income
(17)
Net income
41
Free cash flow
(25)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2016 to FY2019
-20.4%
Revenue, 5 yearsFY2014 to FY2019
-10.1%
Net income, 5 yearsFY2014 to FY2019
n/m

Assertio Therapeutics, Inc financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2019FY2018ChangeSource
Revenue$229.5 million$311.8 million-26.4%10-K 2020-03-10 · proof
Operating income-$194.4 million$43.7 million-545.3%10-K 2020-03-10 · proof
Net income-$217.2 million$36.9 million-688.5%10-K 2020-03-10 · proof
Cash from operating activities$90.5 million$72.5 million+24.8%10-K 2020-03-10 · proof
Free cash flow$89 million$67 million+32.8%10-K 2020-03-10 · proof
Total assets$527.2 million$932.9 million-43.5%10-K 2020-03-10 · proof
Total liabilities$469.2 million$712.5 million-34.1%10-K 2020-03-10 · proof
Cash and cash equivalents$42.1 million$110.9 million-62%10-K 2020-03-10 · proof
What was Assertio Therapeutics, Inc's revenue in fiscal 2019?
Assertio Therapeutics, Inc reported revenue of $229.5 million for fiscal 2019 (the year ended Dec 31, 2019), against $311.8 million the year before (-26.4%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
What was Assertio Therapeutics, Inc's operating income in fiscal 2019?
Assertio Therapeutics, Inc reported operating income of -$194.4 million for fiscal 2019 (the year ended Dec 31, 2019), against $43.7 million the year before (-545.3%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
What was Assertio Therapeutics, Inc's net income in fiscal 2019?
Assertio Therapeutics, Inc reported net income of -$217.2 million for fiscal 2019 (the year ended Dec 31, 2019), against $36.9 million the year before (-688.5%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
What was Assertio Therapeutics, Inc's cash from operating activities in fiscal 2019?
Assertio Therapeutics, Inc reported cash from operating activities of $90.5 million for fiscal 2019 (the year ended Dec 31, 2019), against $72.5 million the year before (+24.8%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
What was Assertio Therapeutics, Inc's free cash flow in fiscal 2019?
Assertio Therapeutics, Inc reported free cash flow of $89 million for fiscal 2019 (the year ended Dec 31, 2019), against $67 million the year before (+32.8%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
What are Assertio Therapeutics, Inc's total assets?
As of Dec 31, 2019, Assertio Therapeutics, Inc reported total assets of $527.2 million, against $932.9 million a year earlier (-43.5%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
What are Assertio Therapeutics, Inc's total liabilities?
As of Dec 31, 2019, Assertio Therapeutics, Inc reported total liabilities of $469.2 million, against $712.5 million a year earlier (-34.1%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC
What are Assertio Therapeutics, Inc's cash and cash equivalents?
As of Dec 31, 2019, Assertio Therapeutics, Inc reported cash and cash equivalents of $42.1 million, against $110.9 million a year earlier (-62%). Source: the 10-K filed with the SEC on Mar 10, 2020. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1005201&period_type=annual&limit=5"

Information only, not investment advice.